Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-18
2007-12-18
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S275000, C544S326000, C544S328000, C544S330000, C544S331000
Reexamination Certificate
active
11210291
ABSTRACT:
The present invention relates to compounds represented by the structural Formula I:or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
REFERENCES:
patent: 4405644 (1983-09-01), Kabbe
patent: 4623662 (1986-11-01), De Vries
patent: 6946476 (2005-09-01), Stamford
patent: 6982267 (2006-01-01), Stamford
patent: 0955293 (1999-11-01), None
patent: WO 96/16542 (1996-06-01), None
patent: WO 97/19682 (1997-06-01), None
patent: WO 98/35957 (1998-08-01), None
patent: WO 99/09024 (1999-02-01), None
patent: WO 99/32111 (1999-07-01), None
patent: WO 99/64394 (1999-12-01), None
patent: WO 00/27845 (2000-05-01), None
patent: WO 00/63171 (2000-10-01), None
patent: WO 01/14376 (2001-03-01), None
patent: WO 01/37826 (2001-05-01), None
Betancur et al., TIPS vol. 18, 372-386, 1997.
Wieland et al., Expert Opin. Investig. Drugs 9(6): 1327-1346, 2000.
Stanley et al., Neuropeptide Y injected in the paraventricular hypothalamus: A powerful stimulant of feeding behavior. Proc. Natl. Acad. Sci, USA (1985) 82:3940-3943.
Billington et al., Effects of Intracerebroventricular injection of neuropeptide Y on energy metabolism, Am. J. Physiol. 260 R321 (1991).
Wahlestedt et al., Neuropeptide Y-Related Peptides and their receptors -are the receptors potential therapeutic drug targets?, Annu. Rev. Pharmacol. Toxicol, (1993) 32:309-353.
Gerald et al. A receptor subtype involved in neuropeptide-Y-induced food intake, Nature (1996) 382: 168-171.
Gehlert et al., Minireview Multiple Receptors for the Pancreatic Polypeptide (PP-Fold) Family: Physiological Implications (44263), Proc. Soc. Exp. Biol. Med., (1998) 218:7-22.
Michel et al., XVI, International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors, Pharmacol. Rev., (1998) 50:143-150.
Hwa et al., Activation of the NPY Y5 receptor regulates both feeding and energy expenditure, AM. J. Physiol., (1999) 277 (46):R1428-R1444.
Bentacur et al., Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy, TIPS (1997) 18:372-386.
Weiland et al., the role of NPY in metabolic homeostasis: implications for obesity therapy, Expert Opinion Investig. Drugs (2000) 9(6):1327-1346.
West Anthony, R. Solid State Chemistry and its Application (1988) pp. 358, 365.
Dong Youhao
McCombie Stuart W.
Stamford Andrew
Wu Yusheng
Kalyanaraman Palaiyur S.
Schering Corporation
LandOfFree
Heteroaryl urea neuropeptide Y Y5 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl urea neuropeptide Y Y5 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl urea neuropeptide Y Y5 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3845692